RxDoctor Payments Data

Rachna Zirath, MD

Internal Medicine · Syracuse, NYNPI 1023006830

Payments from drug & device makers

$907in general payments, 2019–2025

Across 52 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$163
  • Boehringer Ingelheim$111
  • Exact Sciences$103
  • AbbVie$92
  • Novo Nordisk$63
  • Amgen$54
  • plus $320 from 12 others

What the payments were for

  • Food & beverage$89599%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$907 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$75,385
Medicare patients
166
Services billed
997

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$84,818
RybelsusSemaglutide36$44,404
EliquisApixaban44$40,421
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$35,138
TradjentaLinagliptin34$30,667
JardianceEmpagliflozin17$27,038
GlyxambiEmpagliflozin/Linagliptin30$24,959
Spiriva HandihalerTiotropium Bromide15$20,250
JanuviaSitagliptin Phosphate12$18,618
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$5,292
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$5,085
Levothyroxine Sodium286$4,922
Lidocaine15$4,703
SynthroidLevothyroxine Sodium53$3,672
Rosuvastatin Calcium205$2,964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$63$129,22293 claims
Boehringer IngelheimTradjenta, Jardiance, Glyxambi$111$82,66481 claims
PfizerEliquis$27$40,42144 claims
GSKTrelegy Ellipta$163$35,13827 claims
MerckJanuvia$47$18,61812 claims
AbbVieSynthroid$92$3,67253 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →